Latest News

Kamada Announces Collaboration with BGN Technologies for Alpha-1 Antitrypsin Research

Collaboration to be Led by Professor Eli Lewis, One of World’s Leading Alpha-1 Antitrypsin Researchers Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announced today a collaboration for advanced resear
Read More

Amanda Stimpson – Joins the Charity Board

Amanda was diagnosed as being an Alpha end of 2016, she like everybody who is told they have a condition that they have never heard of, was very worried about he future. Amanda found our charity and we were able to put her mind to rest by giving her
Read More

Cori Ruktanoncha becomes a Trustee of the charity

We are very honored that Cori agreed to become the 4th Trustee of our charity. Cori only joined us in the beginning of 2017, but we have been very impressed with the work she has done for us, the way she talks to our members and her willingness to go
Read More

New Logo and Domain name

We announced in April we were donating 10% of all donations to finding a cure for Alpha-1. We now wish to announce 2 more exciting changes. We were the first alpha-1 support group to receive charity status in the UK, Wales and Scotland. We created ou
Read More

UK’s National Health Service Approves Daxas as Treatment for COPD

The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benef
Read More

Kamada Withdraws MAA For Inhaled Alpha-1 Antitrypsin

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has withdrawn the Marketing Authorization Application (MAA) for its proprietary inhaled Alpha-1 Antit
Read More